Zenith Drugs Ltd
Incorporated in 2000, Zenith Drugs Limited is a pharmaceutical company specializing in manufacturing and trading medicines, including generic drugs.[1]
- Market Cap ₹ 108 Cr.
- Current Price ₹ 62.8
- High / Low ₹ 114 / 52.8
- Stock P/E 20.9
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 26.6 %
- ROE 35.1 %
- Face Value ₹ 10.0
Pros
Cons
- Promoter holding has decreased over last quarter: -30.0%
- Company has high debtors of 158 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | |
|---|---|---|
| 92 | 114 | |
| 85 | 104 | |
| Operating Profit | 7 | 10 |
| OPM % | 8% | 9% |
| 1 | 1 | |
| Interest | 2 | 3 |
| Depreciation | 1 | 1 |
| Profit before tax | 4 | 7 |
| Tax % | 29% | 29% |
| 3 | 5 | |
| EPS in Rs | ||
| Dividend Payout % | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 24% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 65% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 35% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Sep 2023 | |
|---|---|---|---|
| Equity Capital | 0 | 0 | 12 |
| Reserves | 12 | 17 | 11 |
| 19 | 26 | 29 | |
| 38 | 55 | 61 | |
| Total Liabilities | 69 | 98 | 112 |
| 10 | 12 | 11 | |
| CWIP | 3 | 0 | 1 |
| Investments | 0 | 0 | 0 |
| 55 | 86 | 101 | |
| Total Assets | 69 | 98 | 112 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | |
|---|---|---|
| 5 | -4 | |
| -5 | 0 | |
| 1 | 5 | |
| Net Cash Flow | 1 | 1 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | |
|---|---|---|
| Debtor Days | 128 | 158 |
| Inventory Days | 96 | 182 |
| Days Payable | 274 | 398 |
| Cash Conversion Cycle | -50 | -57 |
| Working Capital Days | 53 | 84 |
| ROCE % | 27% |
Documents
Announcements
Annual reports
No data available.
Product Portfolio[1]
ORS Powder;
Liquid Orals;
Ointments;
Liquid Externals;
Capsules